+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 4 Actively Recruiting clinical trials

C

Actively Recruiting

Researchers are evaluating whether adding Quizartinib to the combination of Venetoclax and Azacytidine improves overall survival compared to Venetoclax and Azacytidine alone in adults with newly diagnosed acute myeloid leukemia AML who are not suitable for standard induction chemotherapy due to age, other health conditions, or risk factors. This Phase III trial will randomize participants to compare the two treatment regimens. Participants will be assigned to one of two groups the experimental group will receive Azacytidine as a subcutaneous injection daily on days 1 to 7 of each 28-day cycle, Venetoclax orally daily on days 1 to 7, and Quizartinib orally on days 8 to 21 with dose adjusted by FLT3-ITD mutation status. The standard group will receive Azacytidine daily on days 1 to 7 and Venetoclax daily for 28 days in each 28-day cycle. Treatment continues until disease progression, unacceptable side effects, withdrawal, or other protocol-defined reasons. During the study, participants will have regular clinical visits and follow-up assessments, with survival data collected every three months for two years after the last participant finishes treatment. Researchers will monitor overall survival over four years as the primary outcome, along with event-free survival and complete response rates. Safety and treatment effects will be tracked throughout the study period.

Age: 18Years +All GendersPhase 3
52 locations
D

Actively Recruiting

Researchers are conducting an observational study to develop and validate a specific questionnaire for women with diastasis recti abdominis DRA, a condition where the abdominal muscles separate along the midline. DRA affects many women postpartum and can lead to symptoms like lower back, pelvic, and abdominal pain, urinary incontinence, and negative impacts on body image and quality of life. The study aims to create a tool that evaluates these symptoms and their consequences beyond just anatomical measurement of muscle separation. The study involves several stages a systematic literature review to identify relevant symptoms and impacts, an online survey to gather patient-reported experiences, expert panel review to refine questionnaire items, and pilot testing with women who have DRA. After finalizing the questionnaire, researchers will validate it by assessing its reliability and accuracy in a group of adult women attending a physiotherapy clinic. Participants will also complete comparative questionnaires to measure quality of life, gastrointestinal symptoms, functioning, body image, social relationships, and psychological distress. Participants will complete the newly developed questionnaire and related surveys at the start and again after 7 to 10 days to assess consistency over time. The study involves collecting demographic data and detailed self-reported measures regarding DRA symptoms and their effects. Researchers will analyze the questionnaires psychometric properties to ensure it effectively captures the impact of DRA on womens lives. The total participation includes initial assessments and a follow-up to evaluate test-retest reliability.

Age: 18Years - 65YearsFEMALE
2 locations
O

Actively Recruiting

Researchers are conducting an observational study to assess the safety of immunotherapy for treating Hymenoptera venom allergy, which is an allergic reaction to stings from insects like bees Apis mellifera or wasps Vespula spp.. The study also aims to evaluate how patients quality of life changes before and after receiving immunotherapy. This research will take place across multiple centers in Spain and gather data prospectively. Participants in this study are people aged 14 years and older who are allergic to Hymenoptera venom and have been recommended to receive immunotherapy with VENOX, an allergy vaccine targeting the venom of wasps or bees. The study involves monitoring patients receiving this immunotherapy as part of their clinical care, without any placebo or control group, focusing on real-world treatment safety and patient experience. During the study, participants will be followed for up to 12 months to track any adverse reactions to the immunotherapy and allergic reactions to natural insect stings. Quality of life will be assessed using questionnaires before and after treatment. Researchers will also evaluate immune response at 6 and 12 months and monitor treatment effectiveness once maintenance dosing is reached. Data collection will include safety, tolerability, and patient-reported outcomes to understand the impact of immunotherapy in real clinical settings.

Age: 14Years +All Genders
9 locations
P

Actively Recruiting

This research aims to analyze psychosocial protective factors and their association with clinical and functional outcomes in adults hospitalized with dual diagnosis, which means having both a mental disorder and a substance use disorder. The study is observational, cross-sectional, and conducted at a single general hospital. It addresses the challenge that patients with dual diagnosis often face greater clinical severity, functional impairment, and treatment difficulties. The study involves collecting sociodemographic, clinical, and psychosocial data from hospitalized adult patients diagnosed with dual diagnosis. Standardized assessment tools and clinical records will be used without introducing any experimental treatments or altering usual care. No investigational drugs or devices will be administered. Participants will be assessed during their hospital stay, with data collected at baseline within 72 hours of admission and at discharge after an average stay of 10 to 14 days. Researchers will measure medication adherence, clinical severity, quality of life, self-rated health, and suicidal ideation using standardized questionnaires and clinical records. The findings aim to support better, more patient-centered care for this population.

Age: 18Years +All Genders
1 location